159 related articles for article (PubMed ID: 7511758)
1. Renal morphology and function in dogs after treatment with the angiotensin-converting enzyme inhibitor quinapril.
Susick RL; Dominick MA; Ulloa HM; Pegg DG
J Cardiovasc Pharmacol; 1994 Feb; 23(2):275-82. PubMed ID: 7511758
[TBL] [Abstract][Full Text] [Related]
2. Effects of the angiotensin-converting enzyme inhibitor quinapril on renal function in rats.
Graziano MJ; Dethloff LA; Griffin HE; Pegg DG
Arch Int Pharmacodyn Ther; 1993; 324():87-104. PubMed ID: 8297189
[TBL] [Abstract][Full Text] [Related]
3. Renal structure and function in rats after suprapharmacologic doses of quinapril, an angiotensin-converting enzyme inhibitor.
MacDonald JR; Susick RL; Pegg DG; Dominick MA
J Cardiovasc Pharmacol; 1992 Feb; 19(2):282-9. PubMed ID: 1376798
[TBL] [Abstract][Full Text] [Related]
4. ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats.
Ono H; Ono Y; Frohlich ED
Hypertension; 1996 Feb; 27(2):176-83. PubMed ID: 8567038
[TBL] [Abstract][Full Text] [Related]
5. Improved survival in rats administered NG-nitro L-arginine methyl ester due to converting enzyme inhibition.
Michel JB; Xu Y; Blot S; Philippe M; Chatellier G
J Cardiovasc Pharmacol; 1996 Jul; 28(1):142-8. PubMed ID: 8797148
[TBL] [Abstract][Full Text] [Related]
6. Determinants of the renal response to ACE inhibition in patients with congestive heart failure.
Gottlieb SS; Robinson S; Weir MR; Fisher ML; Krichten CM
Am Heart J; 1992 Jul; 124(1):131-6. PubMed ID: 1615796
[TBL] [Abstract][Full Text] [Related]
7. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients.
Hausberg M; Barenbrock M; Hohage H; Müller S; Heidenreich S; Rahn KH
Hypertension; 1999 Mar; 33(3):862-8. PubMed ID: 10082500
[TBL] [Abstract][Full Text] [Related]
8. Quinapril, an angiotensin converting enzyme inhibitor, prevents cardiac hypertrophy during episodic hypertension.
Julius S; Li Y; Brant D; Krause L; Taylor D
Hypertension; 1991 Jun; 17(6 Pt 2):1161-6. PubMed ID: 1828458
[TBL] [Abstract][Full Text] [Related]
9. Preclinical toxicology studies with the angiotensin-converting enzyme inhibitor quinapril hydrochloride (Accupril).
McGuire EJ; Anderson JA; Gough AW; Herman JR; Pegg DG; Theiss JC; de la Iglesia FA
J Toxicol Sci; 1996 Nov; 21(4):207-14. PubMed ID: 8959644
[TBL] [Abstract][Full Text] [Related]
10. Endothelin-1 upregulation in the kidney of uninephrectomized spontaneously hypertensive rats and its modification by the angiotensin-converting enzyme inhibitor quinapril.
Largo R; Gómez-Garre D; Liu XH; Alonso J; Blanco J; Plaza JJ; Egido J
Hypertension; 1997 May; 29(5):1178-85. PubMed ID: 9149684
[TBL] [Abstract][Full Text] [Related]
11. Fertility and perinatal/postnatal studies in rats with the angiotensin-converting enzyme inhibitor, quinapril.
Dostal LA; Kim SN; Schardein JL; Anderson JA
Fundam Appl Toxicol; 1991 Nov; 17(4):684-95. PubMed ID: 1778358
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of quinapril and quinaprilat in patients with congestive heart failure.
Begg EJ; Robson RA; Ikram H; Richards AM; Bammert-Adams JA; Olson SC; Posvar EL; Reece PA; Sedman AJ
Br J Clin Pharmacol; 1994 Mar; 37(3):302-4. PubMed ID: 8198942
[TBL] [Abstract][Full Text] [Related]
13. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
Plosker GL; Sorkin EM
Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326
[TBL] [Abstract][Full Text] [Related]
14. Quinapril--a preclinical review of the pharmacology, pharmacokinetics, and toxicology.
Kaplan HR; Taylor DG; Olson SC; Andrews LK
Angiology; 1989 Apr; 40(4 Pt 2):335-50. PubMed ID: 2539761
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue.
Fabris B; Chen BZ; Pupic V; Perich R; Johnston CI
J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S6-13. PubMed ID: 1691409
[TBL] [Abstract][Full Text] [Related]
16. Renal and vascular consequences of the chronic nitric oxide synthase inhibition. Effects of antihypertensive drugs.
Navarro-Cid J; Maeso R; Rodrigo E; Muñoz-García R; Ruilope LM; Lahera V; Cachofeiro V
Am J Hypertens; 1996 Nov; 9(11):1077-83. PubMed ID: 8931832
[TBL] [Abstract][Full Text] [Related]
17. The subtype 2 of angiotensin II receptors and pressure-natriuresis in adult rat kidneys.
Liu KL; Lo M; Grouzmann E; Mutter M; Sassard J
Br J Pharmacol; 1999 Feb; 126(3):826-32. PubMed ID: 10188997
[TBL] [Abstract][Full Text] [Related]
18. Ultrastructural juxtaglomerular cell changes in normotensive rats treated with quinapril, an inhibitor of angiotensin-converting enzyme.
Dominick MA; Bobrowski WF; Metz AL; Gough AW; MacDonald JR
Toxicol Pathol; 1990; 18(3):396-406. PubMed ID: 2267499
[TBL] [Abstract][Full Text] [Related]
19. Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
Ishimitsu T; Honda T; Ohta S; Akashiba A; Takahashi T; Kameda T; Yoshii M; Minami J; Takahashi M; Ono H; Matsuoka H
Am J Hypertens; 2006 Dec; 19(12):1233-40. PubMed ID: 17161768
[TBL] [Abstract][Full Text] [Related]
20. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
